$COGT
Cogent Biosciences, Inc.

2021 Q1 Form 10-Q Financial Statement

#000156459021026737 Filed on May 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q4 2020 Q1
Revenue $0.00 $0.00 $7.031M
YoY Change -100.0% -100.0% 130.3%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.590M $5.350M $3.670M
YoY Change 25.07% 98.88% 47.39%
% of Gross Profit
Research & Development $8.210M $6.110M $9.498M
YoY Change -13.56% -40.97% -23.42%
% of Gross Profit
Depreciation & Amortization $20.00K $20.00K $300.0K
YoY Change -93.33% -93.55% -9.09%
% of Gross Profit
Operating Expenses $12.80M $11.46M $9.498M
YoY Change 34.77% -12.18% -23.42%
Operating Profit -$6.141M
YoY Change -48.14%
Interest Expense $130.0K $70.00K $50.00K
YoY Change 160.0% 16.67% -66.67%
% of Operating Profit
Other Income/Expense, Net $1.072M $20.00K $47.00K
YoY Change 2180.85% -68.67%
Pretax Income -$11.73M -$11.34M -$6.090M
YoY Change 92.61% -593.04% -47.9%
Income Tax
% Of Pretax Income
Net Earnings -$11.73M -$11.34M -$6.094M
YoY Change 92.45% -593.69% -47.87%
Net Earnings / Revenue -86.67%
Basic Earnings Per Share
Diluted Earnings Per Share -$336.3K -$592.2K -$808.8K
COMMON SHARES
Basic Shares Outstanding 30.61M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q4 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $230.7M $242.2M $29.60M
YoY Change 679.39% 547.59% -55.89%
Cash & Equivalents $232.0M $242.2M $30.86M
Short-Term Investments
Other Short-Term Assets $1.300M $2.700M $1.600M
YoY Change -18.75% 125.0% 100.0%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $232.1M $244.9M $31.19M
YoY Change 644.27% 503.37% -55.39%
LONG-TERM ASSETS
Property, Plant & Equipment $4.300M $134.0K $1.570M
YoY Change 173.89% -92.82% -47.01%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.300M $1.300M $1.300M
YoY Change 0.0% 204.45% 53.66%
Total Long-Term Assets $5.510M $6.004M $7.754M
YoY Change -28.94% -32.02% -31.86%
TOTAL ASSETS
Total Short-Term Assets $232.1M $244.9M $31.19M
Total Long-Term Assets $5.510M $6.004M $7.754M
Total Assets $237.6M $250.9M $38.94M
YoY Change 510.21% 407.69% -52.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $315.0K $732.0K $628.0K
YoY Change -49.84% -77.0% -65.8%
Accrued Expenses $3.800M $5.800M $6.900M
YoY Change -44.93% -26.58% 11.29%
Deferred Revenue $841.0K
YoY Change -95.03%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.242M $13.09M $9.250M
YoY Change -10.9% -1.16% -64.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.600M $3.200M $4.000M
YoY Change -35.0% -27.27% -28.57%
Total Long-Term Liabilities $2.600M $3.200M $4.000M
YoY Change -35.0% -27.27% -28.57%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.242M $13.09M $9.250M
Total Long-Term Liabilities $2.600M $3.200M $4.000M
Total Liabilities $10.85M $16.25M $13.24M
YoY Change -18.06% -8.0% -58.62%
SHAREHOLDERS EQUITY
Retained Earnings -$198.7M -$130.0M
YoY Change 60.38% 25.29%
Common Stock $322.5M $155.7M
YoY Change 107.18% 1.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $226.8M $234.7M $25.70M
YoY Change
Total Liabilities & Shareholders Equity $237.6M $250.9M $38.94M
YoY Change 510.19% 407.69% -52.09%

Cashflow Statement

Concept 2021 Q1 2020 Q4 2020 Q1
OPERATING ACTIVITIES
Net Income -$11.73M -$11.34M -$6.094M
YoY Change 92.45% -593.69% -47.87%
Depreciation, Depletion And Amortization $20.00K $20.00K $300.0K
YoY Change -93.33% -93.55% -9.09%
Cash From Operating Activities -$11.37M -$9.370M -$7.893M
YoY Change 44.0% 11.02% -31.47%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $38.00K
YoY Change 245.45%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -85.00K 122.1M 73.00K
YoY Change -216.44% 563.64%
NET CHANGE
Cash From Operating Activities -11.37M -9.370M -7.893M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities -85.00K 122.1M 73.00K
Net Change In Cash -11.45M 112.8M -7.820M
YoY Change 46.43% -1434.56% -327.13%
FREE CASH FLOW
Cash From Operating Activities -$11.37M -$9.370M -$7.893M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$9.370M -$7.893M
YoY Change 11.15% -31.72%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Assets
Assets
237610000
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
315000
CY2021Q1 cogt Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
2750000
CY2021Q1 cogt Contingent Value Right Liability Current
ContingentValueRightLiabilityCurrent
3060000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
8242000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2605000
CY2021Q1 us-gaap Liabilities
Liabilities
10847000
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7031000
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37194267
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9000000
CY2021Q1 cogt Issuance Of Common Stock Value To Settle Liability
IssuanceOfCommonStockValueToSettleLiability
2043000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9498000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.81
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7534187
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37194267
CY2021Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
604000
CY2021Q1 cogt Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
-343000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
38000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
31762000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1072000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-11728000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-6094000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11696000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6094000
CY2021Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
260000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1521000
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
35000
CY2020Q1 us-gaap Treasury Stock Retired Cost Method Amount
TreasuryStockRetiredCostMethodAmount
808000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
25702000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-11728000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-6094000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
17000
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
295000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1781000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
769000
CY2020Q1 cogt Noncash Consideration Received From Customer
NoncashConsiderationReceivedFromCustomer
808000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2000000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1392000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
414000
CY2021Q1 cogt Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-446000
CY2020Q1 cogt Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-356000
CY2020Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-427000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-417000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2555000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2029000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1008000
CY2021Q1 cogt Increase Decrease In Operating Leases
IncreaseDecreaseInOperatingLeases
-485000
CY2020Q1 cogt Increase Decrease In Operating Leases
IncreaseDecreaseInOperatingLeases
-387000
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-474000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11366000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7893000
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
38000
CY2020Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
35000
CY2021Q1 cogt Payment To Contingent Value Right Holders
PaymentToContingentValueRightHolders
85000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-85000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
73000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11451000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7820000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38679000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
231994000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30859000
CY2021Q1 us-gaap Convertible Preferred Stock Converted To Other Securities
ConvertiblePreferredStockConvertedToOtherSecurities
16200000
CY2021Q1 us-gaap Stock Issued1
StockIssued1
2043000
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#222222;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.54%;color:#222222;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, revenue recognition, the accrual of research and development expenses, the valuation of the CVR liability and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.</p>
CY2020Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.60
CY2020Q1 us-gaap Restructuring And Related Cost Expected Number Of Positions Eliminated
RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
43
CY2020Q3 us-gaap Share Price
SharePrice
8.80
CY2021Q1 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
0
CY2021Q1 cogt Fair Value Assets Transfers Between Level One Two And Three
FairValueAssetsTransfersBetweenLevelOneTwoAndThree
0
CY2020Q1 cogt Fair Value Assets Transfers Between Level One Two And Three
FairValueAssetsTransfersBetweenLevelOneTwoAndThree
0
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
587000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1443000
CY2021Q1 cogt Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
666000
CY2020Q4 cogt Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
2191000
CY2021Q1 cogt Accrued External Manufacturing Cost Current
AccruedExternalManufacturingCostCurrent
382000
CY2020Q4 cogt Accrued External Manufacturing Cost Current
AccruedExternalManufacturingCostCurrent
161000
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1115000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
984000
CY2021Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2750000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4779000
CY2021Q1 cogt Preferred Stock Including Temporary Equity Shares Authorized
PreferredStockIncludingTemporaryEquitySharesAuthorized
10000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42390225
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1781000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
769000
CY2021Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2023-04-30
CY2021Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2021Q1 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The Company?s option to extend for an additional five-year term.
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
900000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
900000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
594000
CY2021Q1 us-gaap Variable Lease Cost
VariableLeaseCost
178000
CY2021Q1 us-gaap Sublease Income
SubleaseIncome
604000
CY2021Q1 us-gaap Lease Cost
LeaseCost
168000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
772000
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y0M29D
CY2021Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0950
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1830000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2497000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
841000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5168000
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
446000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
4722000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11728000
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6094000
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
32613111
CY2021Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1.00
CY2021Q1 us-gaap Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage
DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage
0.04

Files In Submission

Name View Source Status
0001564590-21-026737-index-headers.html Edgar Link pending
0001564590-21-026737-index.html Edgar Link pending
0001564590-21-026737.txt Edgar Link pending
0001564590-21-026737-xbrl.zip Edgar Link pending
cogt-10q_20210331.htm Edgar Link pending
cogt-20210331.xml Edgar Link completed
cogt-20210331.xsd Edgar Link pending
cogt-20210331_cal.xml Edgar Link unprocessable
cogt-20210331_def.xml Edgar Link unprocessable
cogt-20210331_lab.xml Edgar Link unprocessable
cogt-20210331_pre.xml Edgar Link unprocessable
cogt-ex311_10.htm Edgar Link pending
cogt-ex312_7.htm Edgar Link pending
cogt-ex321_6.htm Edgar Link pending
cogt-ex322_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending